Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Cabozantinib and Durvalumab with or without Tremelimumab in Treating Patients with Stage III-IV Gastroesophageal Cancer and Other Gastrointestinal Malignancies

Trial Status: active

This phase I/II trial studies the side effects and best dose of cabozantinib when given together with durvalumab and tremelimumab in treating patients with stage III-IV gastroesophageal cancer and other gastrointestinal malignancies. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib and durvalumab may work better in treating patients with gastroesophageal cancer and other gastrointestinal malignancies compared to cabozantinib or durvalumab alone.